US FDA's 'Great' Generic Approval Engine Can Be Better, New OGD Director Says
In interview with the Pink Sheet, Sally Choe expresses doubts that setting goals for approval totals is productive, saying the current workflow looks fine.
You may also be interested in...
Republican House Energy and Commerce Committee members say potentially taking a company's revenue for blocking a generic company from obtaining samples, rather than profit, is excessive.
Incoming Office of Generic Drugs Director Sally Choe is largely unfamiliar to industry, but potentially offers a new perspective.
Sally Choe, who has been working in the Office of Translational Sciences, will take over for Kathleen Uhl in March.